Targeting solid tumors with enhanced specificity; Developing CAR T therapies for pediatric cancers; Advancing preclinical studies for hematologic cancers; Engineering CAR T cells to overcome therapeutic resistance; Collaborating on antibody drug conjugate development
Founders are Stanford researchers with significant expertise; Recent publication in Nature on CAR T technology; Backed by Samsara BioCapital; Leadership team with extensive industry experience